4/24/18 5:27 PM / by Bree Gorman, MPH posted in Antireflux Surgery, GERD

1 Comment

Houston, TX, 04/24/18: Respiratory Technology Corporation (Restech) announced today the asset acquisition of Mederi Therapeutics Inc. In response to the increasing need for therapeutic options to address the growing conditions of reflux disease and gastric disease, Restech welcomes the addition Stretta® and Secca® technology to their product portfolio. These new innovative product lines complement Restech’s existing diagnostic devices with therapeutic solutions, provide additional clinical pathways, and broaden Restech’s global distribution network.

Read More

Diagnosing extraesophageal symptoms: which method of pH monitoring is best?

12/1/17 10:55 AM / by Kathy Bach posted in Reflux diagnosis, LPR, pH monitoring, ENT, GI, GERD, 2017



Restech’s pH system was the highlight of new research presented by Dr. Ezra Teitelbaum at the 2017 American College of Surgeons’session on Novel Endoscopic and Minimally Invasive Techniques for Esophageal Dysmotility and Reflux Disease. Dr. Teitelbaum (Assistant Professor of Surgery and Medical Education at Northwestern University) collaborated with Dr. Steven DeMeester (President and Executive Director of the Foundation for Research and Education in Esophageal and Foregut Disorders) on a study comparing the results of different pH monitoring tests in patients off antisecretory medications.  

Read More

The Restech Blog

Reflux Diagnosed. Reflux Treated.

Our blog articles aim to answer your questions about diagnostic and therapeutic approaches to reflux disease. Restech's pH system provides real-time pH data to help physicians develop the most targeted reflux treatment plan possible. Our new Stretta therapy is an effective alternative to anti-reflux surgery or implanted devices. It has been shown to reduce dependency on PPIs and improve reflux-related quality of life. 


Recent Posts